MOSCOW, March 16. /TASS/. US-based Eli Lilly will keep current availability of pharmaceuticals from the essential drug list for Russian patients, press service of the Russian unit of the company told TASS.
"Eli Lilly maintains current availability of pharmaceuticals from the essential drug list for patients in Russia for the time being. The company does not halt ongoing clinical trials in Russia but will temporarily suspend the start of new trials. The company for the time being halts investments and projects aimed at promotion of company’s products," the press service said.
Merck continues its operations in Russia, the Russian unit of the corporation told TASS.
"Our key priorities for the time being are safety of employees and support of deliveries to distributors ensuring availability of drugs for patients in Russia and CIS countries. We do our best to support continuous deliveries of medications and products to patients and clients. It is too early to speak about plans," the press service said.